Shared By A COPD Specialist Summoned By A Leading Global Lung Authority — For Patients Still Struggling After Years Of Inhalers, Steroids And Oxygen Therapy
If you identified with even 2 or more of these symptoms, a COPD specialist working with a leading global lung authority believes the underlying cause may be Catalytic Carbon — an invisible toxin accumulating in your alveoli with every breath — and that a natural morning protocol using two specific compounds may help support healthier breathing.
WATCH THE FREE COPD PRESENTATIONThe real reason COPD keeps progressing may have nothing to do with effort or willpower. Researchers now believe an invisible environmental toxin — one that standard treatments were never designed to address — may be a key contributing factor.
A toxic particle produced by cars, factories, and burning fuels may accumulate inside the alveoli — the tiny air sacs responsible for oxygen transfer. Research suggests it can trigger chronic inflammation and contribute to the fibrosis that gradually narrows the airways over time. Studies indicate it's present in 93% of Americans — smokers and non-smokers alike.
Inhalers force more air in. Steroids reduce inflammation temporarily. Oxygen therapy compensates for lost function. None of them were designed to address Catalytic Carbon accumulation or support alveolar health. This may help explain why many COPD patients report limited long-term improvement despite years of treatment.
Researchers studying a Pacific island tribe with very low COPD rates — despite lifelong smoking — identified two compounds used in their daily morning ritual. Mullen leaf is believed to help bind to Catalytic Carbon and support its natural expulsion. Eucalyptus extract may then help dilate the airways and support healthier lung tissue — a combination now being studied in respiratory health research.
Note: Catalytic Carbon accumulation may not always appear clearly on standard X-rays — which researchers believe may be one reason conventional treatments focus on symptom management rather than the underlying environmental factors.
How standard approaches compare to what emerging respiratory research now suggests.
Here are the three things COPD patients want to know most — before watching the free presentation.